2021
DOI: 10.1016/j.jaci.2021.05.023
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of hereditary angioedema: When the goal is having a normal life

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(14 citation statements)
references
References 10 publications
0
13
0
1
Order By: Relevance
“… 1 Treatments for acute attacks must be given intravenously or subcutaneously, and available options include ecallantide (kallikrein inhibitor), intravenous C1 inhibitor protein, and icatibant (bradykinin B2 receptor antagonist). 1 , 4 Icatibant and intravenous C1 inhibitor protein can be self-administered; only treatment with ecallantide requires administration by a health-care professional. Some of these have undesirable side effects, including hypersensitivity reactions, anaphylaxis, and/or a burning sensation at the injection site.…”
Section: Mainstays Of Treatmentsmentioning
confidence: 99%
See 1 more Smart Citation
“… 1 Treatments for acute attacks must be given intravenously or subcutaneously, and available options include ecallantide (kallikrein inhibitor), intravenous C1 inhibitor protein, and icatibant (bradykinin B2 receptor antagonist). 1 , 4 Icatibant and intravenous C1 inhibitor protein can be self-administered; only treatment with ecallantide requires administration by a health-care professional. Some of these have undesirable side effects, including hypersensitivity reactions, anaphylaxis, and/or a burning sensation at the injection site.…”
Section: Mainstays Of Treatmentsmentioning
confidence: 99%
“…Some of these have undesirable side effects, including hypersensitivity reactions, anaphylaxis, and/or a burning sensation at the injection site. 2 , 4 …”
Section: Mainstays Of Treatmentsmentioning
confidence: 99%
“…Despite advances in treatment, the burden of HAE remains heavy for patients. Indeed, there is a significant humanistic burden associated with HAE, particularly due to disease heterogeneity and the unpredictability of disabling HAE attacks, making them difficult to characterize and effectively manage [ 55 , 56 ]. Attacks can occur in the absence of an identifiable event.…”
Section: Quality Of Life (Qol) In Patients With Haementioning
confidence: 99%
“…However, in consideration of the adverse effects of androgen treatment and need to improve patient QoL, androgens are no longer the first treatment choice recommended by guidelines in the global consensus [ 59 ]. The availability and cost of new treatments for HAE are important issues in China and Brazil [ 9 , 55 ]. In the last decade, several new drugs and new indications for old drugs have played a role in the management of HAE.…”
Section: Safe and Effective Long-term Prophylactic Treatment Alternat...mentioning
confidence: 99%
“…O Angioedema Hereditário (AEH) é um edema não inflamatório, assimétrico e de origem autossômica dominante, atingindo um em cada 50.000 indivíduos. Caracterizada por ser autolimitada, esta doença restringe-se ao tecido subcutâneo ou submucoso e ocorre devido ao aumento da permeabilidade vascular e da vasodilatação, causando o inchaço da região atingida (Giavina-Bianchi et al, 2018;Serpa et al, 2021;Arruda & Leme Ferriani, 2021). Os episódios de AEH são recorrentes, devido a mutação no gene SERPING1 que decorre em função da deficiência do inibidor de C1 (C1-INH), induzindo a produção, em excesso, do mediador vasoativo bradicinina, de modo a afetar diversos órgãos, sendo que um terço das crises se localizam na região abdominal e outro terço na região dos membros (Busse & Christiansen, 2020;.…”
Section: Introductionunclassified